Objectives: Spinal cord stimulation (SCS) has emerged as an appropriate modality of treatment for intractable chronic pain. The present study examines variations in SCS trial-to-permanent conversion rates based on provider types performing the procedure.
INTRODUCTION
Chronic pain affects approximately 100 million individuals in the United States, with a significant economic impact resulting in $635 billion in health care costs annually (1) . Traditional treatment with pharmacological therapies has been shown to inadequately treat neuropathic pain with nearly 20% of chronic pain patients reporting poor pain relief with opioid control (2, 3) . In the context of these poor outcomes and high cost burden, spinal cord stimulation (SCS) has emerged an appropriate modality of treatment. SCS has been shown to reduce pain intensity, and improve quality of life and overall burden of pain management (4, 5) .
Previously a last-line treatment, SCS is now considered an effective treatment for a variety of neuropathic pain conditions. SCS is particularly effective in treating neuropathic pain derived from failed back surgery syndrome, complex regional pain syndrome (CRPS), peripheral neuropathy, phantom limb pain, angina, and ischemic limb pain (6) (7) (8) . The procedure involves a short trial of 3-7 days, typically performed in an outpatient setting, in which a temporary stimulator lead is implanted to determine whether adequate pain relief is achieved. If significant (>50%) pain relief is seen during the trial, a complete (permanent) system is implanted (9) , and successful trialto-permanent conversion is achieved.
As a growing body of evidence demonstrates that SCS is both more cost-effective and creates better outcomes than conventional opioid therapies, it has become more commonly used. This rise in use has been accompanied by an increasing diversity of providers performing the procedure, which now includes anesthesiologists, pain management, or pain medicine specialists (hereafter anesthesiologists), neurosurgeons, orthopedic surgeons, and physical medicine and rehabilitation (PM&R) specialists. With different surgical and medical disciplines participating in patient selection, implantation, and follow-up, it has also become increasingly clear that SCS outcomes may be influenced by physician expertise in such areas. Furthermore, with a nationwide trial-to-permanent conversion rate recently reported for SCS at 41.4%, there is a need to evaluate and address factors that have the potential to improve outcomes (10) .
Although there is ample evidence that SCS is best for managing certain types of neuropathic pains, little work has been done to understand whether provider type impacts the success of SCS procedures and influences patient outcomes or healthcare resource utilization. The availability of large secondary data bases that track outcome measures and overall healthcare spending across government, community, and academic institutions provides a unique lens through which to observe how different provider types may impact these important metrics for successful management of chronic pain. In this large, retrospective study, we used patient data from the Truven MarketScan data base to examine variations in SCS trial-topermanent conversion rates from 2007 to 2012 based on the specialty performing the procedure. We hypothesize that specialties traditionally trained in surgical implantation of SCS systems will have a higher trial-to-permanent conversion rates and will better utilize healthcare resources.
METHODS

Data Source
Truven Marketscan was utilized to design a retrospective review and establish a patient cohort for analysis. Marketscan is a national data base that includes information from Commercial Claims and Encounters, Medicare Supplemental and Coordination of Benefits, and Medicaid data bases. Patients have an encrypted ID that serves a unique identifier as well as allows for de-identification and a linkage variable across different files. The data base is constructed from paid claims from 100 data sources, and includes United States inpatient admissions, inpatient services, outpatient services, and enrollment tables between 2007 and 2012, which is de-identified and collected from a third party, requiring no patient contact or consent.
Outcome Measures
Trial-to-permanent conversion rates comprised the main outcome measure. A successful trial was defined by percutaneous lead implant trial followed by permanent implantation. Failed trial was defined by percutaneous lead implant not accompanied by an internal pulse generator (IPG) implant. Separate cohorts for chronic pain patients were obtained based on successful vs. failed trial with respect to each provider type performing the implant.
Patient Selection and Cohorts
Unique instances of SCS trials were identified from the Marketscan national data base. These individuals underwent implantation of a percutaneous SCS lead (CPT-4: 63650) or a paddle SCS lead (CPT: 63655) without a simultaneous implantation of a percutaneous pulse generator (CPT-4: 63685) (Supporting Information Table 1 ). Inclusion criteria included age at the first SCS lead implantation 18 years old and available medication data in the data base. The provider inclusion criteria included involvement in a minimum of three SCS trial implants and the provider type, where the latter was represented by at least 100 unique instances to represent providers that typically perform these procedures. Provider types included in our analysis were anesthesiology, PM&R, neurosurgery, and orthopedic surgery. Providers that self-identified as pain management or medicine specialists were grouped together with anesthesiology. Providers without enrollment and baseline data were excluded in our study. Any instances that were coded ambiguously were also excluded from analyses including IPG placement one week prior to SCS. This yielded 7667 unique instances of patients undergoing trial implantation (Supporting Information Fig. 1 ). All unique instances of patients were also categorized with ICD-9 pain diagnoses into seven commonly used groupings including back pain, chronic pain syndrome, chronic regional pain syndrome, degenerative spine disease, neuritis/radiculitis, limb pain, and post-laminectomy syndrome (Supporting Information Table 1 ).
Statistical Analysis
Descriptive statistics were reported and separated by provider type performing procedure. Univariate logistic regression model was used to test the significance of provider type. Continuous variables such as trial-to-permanent conversion rates, explant rates, pain diagnosis, gender, employment status, age, geographic region were summarized using means, standard deviations, medians, and quartiles. Variables of healthcare resource utilization were also included to understand the effect of provider type on cost outcomes. A multivariate logistic regression model was used to quantify the likelihood of permanent conversion using categorical variables. These covariates included age at first SCS lead implant, gender, year of procedure, insurance source, employment status, provider type, and Charlson score. Kruskal Wallis test was used for the group difference for the continuous variable, and chi-square test was used for the group difference for categorical variables. Further, variables of healthcare resource utilization were included to understand the effect of provider type on cost outcomes. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) are reported for trial-topermanent conversion rates. All analyses were conducted with SAS version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Patient Cohort
About 7667 unique instances of patients that underwent a percutaneous SCS trial between 2007 and 2012 were identified. There were four total provider types that were included in the study. The patient cohort was grouped based on these provider types, which included anesthesiologists (62.8% of all procedures), neurosurgery (22.0%), orthopedic surgery (10.2%), and PM&R (5.3%). Overall, 60.0% of patients were female, 21.4% were actively employed and 73.6% were commercially insured. Average Charlson score did not significantly differ among the providers, with the average score being 0 among 50.1% of patients. Majority of the patients (67.6%) were located in the Southern region. Description statistics are provided in Table 1 .
Predictors of Conversion Rates
Overall, 4842 patients (63.2%) underwent a permanent SCS implantation after the initial trial. Two thousand eight hundred and 
Provider-Based Outcomes
Provider type was a significant predictor of trial-to-permanent conversion rates (Table 1) . Overall, higher conversion rates were found among neurosurgeons (91.9% of all patients had successful An overwhelming majority of anesthesiologists and PM&R implanted percutaneous leads only (95.3 and 93.6% of all implants) compared to neurosurgeons and orthopedic surgeons (13.2 and 36.2% of all implants). Neurosurgeons (13.3%) and orthopedic surgeons (7.1%) implanted significantly more paddle implants compared to anesthesiologists (0.2%) and PM&R (0.5%). Overall, paddle trials comprised 3.8% of all implants.
While explant rates were slightly higher among the anesthesiologists (12.1% of implanted individuals) and lower among the neurosurgeons (10.7%), overall, there were no significant differences among the providers (median explant rate 11.6%; p 5 0.546). Similarly, average time to explant was not significantly different among the providers (median time to explant 243.0 days; p 5 0.681).
The predominant diagnoses for each provider type are listed in Table 2 . Overall, the median number of comorbid pain diagnoses for each group was four. A prior history of back pain was most commonly present in the orthopedic surgery patient cohort (75.6%), followed by PM&R (73.5%), neurosurgery (72.4%), and anesthesiology (65.2%; overall median 68.3%, p < 0.0001). A prior history of CRPS was most commonly found among the anesthesiology patient cohort (9.3%), followed by PM&R (8.3%), neurosurgery (7.3%), and orthopedic surgery (5.2%; overall median 8.4%, p 5 0.0004). Diagnosis of degenerative spine disease was most common among the orthopedic surgery patient cohort (74.5%) and least common among the anesthesiology cohort (65.2%; overall median 67.1%, p < 0.0001). A diagnosis of neuritis/radiculitis was most commonly present among PM&R (77.9%) and least common among the anesthesiology cohort (72.5%; overall median 73.4%, p 5 0.0194). The provider composition of limb pain diagnosis included neurosurgery (26.9%), PM&R (27.0%), orthopedic surgery (25.0%), and anesthesiology (23.5%; overall median 24.6%, p 5 0.0227). A diagnosis of postlaminectomy syndrome did not significantly differ among the groups.
Healthcare Resource Utilization
Trends in healthcare resource utilization are listed in Table 3 . There were no significant differences in the total cost of treatment across the provider types (overall median cost $8343.6; p 5 0.361) or the total number of inpatient admissions (p 5 0.0776). Total cost attributed to pain encounters was higher amongst the orthopedic surgeons (median $4353.4) and lowest for anesthesiology (median $3436.3) and neurosurgery (median $3759.5; p 5 0.0011). Time to permanent IPG implantation after SCS lead was shortest among the anesthesiologists (median 32.0 days) and longest among the neurosurgeons (median 35.0 days; p 5 0.0006).
DISCUSSION
Chronic pain is a major public health care concern with the yearly cost of treatment at approximately $635 billion in the United States alone (1) . In this study, we utilized the MarketScan data base to design a large, retrospective study trial and identify 7667 patients that underwent a percutaneous or paddle SCS trial. Data were classified across four provider types including anesthesiology, PM&R, neurosurgery, and orthopedic surgery. We subsequently analyzed trial-to-permanent conversion rates associated with different provider types, as well as independent factors associated with a successful conversion. Variables of healthcare resource utilization included total cost of treatment and cost of pain prescriptions. Our hypothesis was largely supported, showing increased conversion rates among specialties that traditionally perform surgical implantation of SCS systems. However, there were no significant differences in healthcare resource utilization across the providers. A primary finding in our study relates to trial-to-permanent conversion rates across provider types that performed SCS procedures (Fig. 1) . Anesthesiologists performed the majority of the SCS implantations in our patient cohort. Both neurosurgery and orthopedic surgery had significantly higher conversion rates compared to other specialties, and accounted for 32.2% of all implants (Table 1) . PM&R was associated with significantly lower conversion rates. Furthermore, due to increased trial-to-permanent conversion rates among some provider groups, we evaluated whether this also translated into higher explant rates. We found no significant differences, and explant rates and average days to explantation remained similar across all providers. Overall, age was distributed equally across the provider types. While female gender was an independent predictor of a successful conversion in our study (Table 4) , gender distribution in itself was not significantly different across the providers. Finally, while there were no differences in total cost of treatment or inpatient admissions across the major providers, differences were found for the total cost of pain encounters prior to SCS implantation, which was lowest among the anesthesiologists, and highest among the orthopedic surgeons.
Higher trial-to-permanent conversion rates among the neurosurgeons and orthopedic surgeons may be attributed to different factors. One of these may be availability of postresidency training programs targeting surgical experience with techniques involved in SCS. However, as discussed in previous efforts to standardize guidelines (11) , surgical experience alone may not account for the increased success. While patient selection criteria across the different providers could not be measured in this study, such criteria might further contribute to higher conversion rates among the surgical specialties in our study, such that these patients may have already failed conventional medical management. We also considered the impact of differences in the predominant pain diagnoses among the providers ( Table 2 ). The median number of pain diagnoses across all providers was four. Significant albeit small differences were found among the majority of the pain diagnoses. Most notably, a prior history of back pain and degenerative spine disease was most common among the orthopedic surgeons and least common among the anesthesiologists. CRPS was most common among the anesthesiologists and least common among the orthopedic surgeons. While certain pain diagnoses such as CRPS carry a lower trial-to-permanent conversion rate and may contribute to the trend observed in our dataset, these alone do not explain the vast differences in trial-topermanent conversion rates that exist among the provider types. Finally, the total number of procedures performed might serve as an indicator of physician experience. Previously, a minimum case load has been suggested as one aspect of core competency in providers performing SCS implantation (11) . Recent work from our group has analyzed how procedure volume predicts conversion rates, as well as healthcare resource utilization (12) . Overall, high volume providers were found to be independent predictors of successful trialto-permanent conversion rates. Thus, it is possible that provider types with higher trial-to-permanent conversion rates are part of practices that see a higher volume of patients.
An important aspect of these findings is consideration of which specialties perform the IPG. Because the surgical specialties often perform both the trial and the IPG permanent implants, one could suggest that there are differing inertias to continue towards permanent based on the trial period (13, 14) . Patients of surgeons do not need a referral for IPG, whereas the patients of non-surgeons may sometimes need a referral if the trial physician does not perform the permanent implantation. Consequently, patient autonomy-where decision to proceed is made by the patient's subjective interpretation of >50% pain improvement-is diluted. However, PM&R specialists and anesthesiologists may have greater inertia to make the referral to a surgeon for IPG placement, whereas surgeon's operative schedules might incentivize subsequent placement. Further, a significantly higher number of paddle implants are performed by neurosurgeons and orthopedic surgeons. Such inertia differences might inflate the conversion rates in surgeons-where it is much harder for a patient to subjectively admit the trial "failed" when their surgery for IPG is already scheduled for the next week. However, we also evaluated the possible consequence of this using explant rates, and did not find significant differences among the provider types. This is similar to evidence in the literature showing poor correlation of explant rates between different providers (15) . Furthermore, average number of days to IPG after trial SCS lead was 34.0 days and similar across all providers, with anesthesiology having shorter (32.0 days) and neurosurgeons with longer (35.0 days) lengths. Nonetheless, while success has been seen in permanent implantation despite poor response in the trial (16), we suggest that SCS training reinforce the importance of patient rating of pain improvement in guiding the scheduling of permanent device placement. Maintaining the integrity of the trial period will importantly remove this as a variable in the comparison of the specialists who perform implants. Ultimately, higher conversion rates among the surgical specialties should be considered multifactorial. Previously, the North American Neuromodulation Society provided guidelines toward adequate training and competency among providers performing SCS in an effort to standardize knowledge across specialties with marked differences in training (11) . As SCS procedures have expanded to include different specialties over the last few decades, so have the challenges in implantation and management of SCS systems that require dedicated multidisciplinary training in an academic setting. Competency in SCS systems extends beyond expertise in surgical techniques, and includes training in epidural access techniques, programming and management of SCS systems, as well as core knowledge in mechanisms of action, appropriate screening, patient selection, and postoperative follow-up with recognition of complications. Indeed, an appropriate SCS practice may include a physician or group of physicians that have been trained to provide care across these facets (11) . Such services would also include an adequate case load and appropriate medical personnel familiar with SCS systems from more than one manufacturer. Existing guidelines by NANS have proposed three tracks to train physicians performing SCS that complete preliminary training across neurosurgery, pain medicine, orthopedic spine surgery, anesthesiology, and interventional pain medicine. Besides desirable competency in core knowledge and management of SCS systems, active participation in at least 25 follow-up a b visits implanted with SCS in the capacity of a primary operator and evaluator must be demonstrated. As more SCS procedures are performed annually in the United States (17, 18) , our study provides the first concrete evidence of variations in success rates with provider type performing SCS trials and implantation, and underscores the importance of standardizing education and training through uniform guidelines. In exploring prognostic factors associated with optimal SCS outcomes, previous studies demonstrated the importance of appropriate patient selection, pain pattern, and physician expertise (19, 20) . Accumulating evidence in the last 20 years has also shown a significant correlation between procedural volume and surgical outcomes (21) (22) (23) . In the past 15 years, a number of randomized control trials and meta-analyses have demonstrated SCS as a therapeutically beneficial and cost-effective approach to chronic pain management in carefully selected patients (24) (25) (26) . Over this same period, the number of SCS procedures by anesthesiologists, PM&R, and orthopedic surgeons have grown to service and provide options to major portions of patients undergoing implantation. Yet successful trial-to-permanent conversion rates for SCS remain below 50% nationwide (10) and the predictors of SCS trial outcome remain poorly understood beyond pain etiology (27, 28) . Going forward, a concerted effort is needed to establish and follow uniform guidelines for standardization of training across the different medical and surgical specialties involved in patient selection, SCS trial and permanent implantation, and follow-up, will prove useful in improving the overall quality of care being offered. This is the first study to show variations in trial-to-permanent conversion rates in different provider specialties that perform SCS trial or permanent implantation, a treatment modality that is being increasingly utilized in treating chronic pain. There are, however, several limitations to this study. First, this is a retrospective cohort analysis that uses unique instances of patients from a Truven MarketScan data base. To address this, we performed univariate and multivariate analysis with regression covariates, and adjustment of appropriate patient and cost-related factors. Second, baseline clinical states and other patient-related factors including pain intensity and quality of life could not be analyzed in the patient cohort. Third, as the data base does not distinguish between the prior training of pain medicine specialists, this group was categorized into a larger group with anesthesiology due to common background training. While both groups had strikingly similar conversion rates, other differences between the two groups may not be ruled out. Fourth, the data base may not take into account the type of procedures or pain encounters that may contribute to varied healthcare resource utilization costs across the different providers. Furthermore, the data base does not account for physician experience, patient selection, or customization of spinal cord stimulation characteristics.
Despite the aforementioned limitations, the comprehensive and inclusive nature of the Truven MarketScan data base provides us a useful trend in trial-to-permanent conversion rates for SCS implantations across various provider types. Follow up studies may utilize separate metrics of healthcare resource utilization to delineate the impact of the results of this study. As SCS trial and permanent implantation becomes more commonly performed, an important component would be addressing the current variations in training and education of providers performing SCS procedures.
CONCLUSION
In this large, nationwide analysis of 7667 patients, we demonstrated significant variations among providers in trial-to-permanent rates for SCS implantations. Our study is the first in literature that provides evidence of significant variation in SCS outcomes among providers. This has implications for development of appropriate training programs for improved competency across provider types that are performing large numbers of SCS procedures. As the field of neuromodulation continues to expand and neurostimulation procedures are performed by an expanding number of medical and surgical specialties, standardization, and guidelines for expected training requirements will ensure quality and optimal outcomes for patients undergoing treatment of chronic pain.
